DIPB vs. SIFIB for Postoperative Analgesia After Hip Surgery
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSivas Numune Hospital
About this trial
This randomized, double-blind clinical trial aims to compare the effectiveness of the Deep Iliacus Plane Block (DIPB) and the Suprainguinal Fascia Iliaca Block (SIFIB) for postoperative pain control in patients undergoing primary total hip arthroplasty. Effective analgesia after hip surgery is essential for early mobilization, reduction of complications, and improved recovery outcomes.
Seventy patients scheduled for elective hip arthroplasty under spinal anesthesia will be randomly assigned to receive either DIPB or SIFIB at the end of surgery. Postoperative pain scores, opioid consumption, motor block, and block-related complications will be evaluated over a 48-hour period.
The study aims to determine whether DIPB provides superior or comparable analgesia with reduced motor blockade compared to SIFIB, thereby contributing to safer and more comprehensive postoperative pain management in hip surgery patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged ≥18 years
ASA physical status I-III
Scheduled for elective primary total hip arthroplasty under spinal anesthesia
Ability to understand the study procedures and provide informed consent
Disqualifiers
Coagulation disorders or anticoagulant therapy contraindicating regional anesthesia
Infection at the block application site
Hemodynamic instability
Known allergy to local anesthetics
Trial design
Design model
Parallel
Treatments tested in this trial
Suprainguinal Fascia Iliaca Block
Procedure/SurgeryUltrasound-guided suprainguinal fascia iliaca compartment block performed at the end of surgery using 0.25% bupivacaine (30-40 mL, weight-adjusted) for postoperative analgesia following primary total hip arthroplasty.
Deep Iliacus Plane Block
Procedure/SurgeryUltrasound-guided deep iliacus plane block performed at the end of surgery using 0.25% bupivacaine (30-40 mL, weight-adjusted) for postoperative analgesia following primary total hip arthroplasty.
Treatment groups
70 Participants
are divided into 2 treatment groupsGroup A: Suprainguinal Fascia Iliaca Block (SIFIB)Experimental treatment 1 intervention
Group B: Deep Iliacus Plane Block (DIPB)Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Postoperative pain intensity
Postoperative pain assessed using the Numeric Rating Scale (NRS; 0 = no pain, 10 = worst pain imaginable) at rest and during movement following total hip arthroplasty.
Time frame
2, 4, 8, 16, 24, and 48 hours postoperativelySecondary outcomes
1
Opioid consumption
Total rescue opioid consumption (intravenous tramadol) administered for postoperative pain management.
Time frame
From the end of surgery to 48 hours postoperatively2
Motor block
Motor blockade assessed using the Modified Bromage Scale (0-3), where higher scores indicate greater motor impairment of the lower extremity following regional anesthesia.
Time frame
4, 8, 16, 24, and 48 hours postoperatively3
Pain during movement
Pain during movement assessed using the Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain), where higher scores indicate greater pain intensity.
Time frame
2, 4, 8, 16, 24, and 48 hours postoperativelySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov